CD38-Targeted Molecular Imaging Probes for Multiple Myeloma: Advances, Challenges, and Opportunities
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01232 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Meng Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, NO.899 Pinghai Road, Suzhou 215006, China. Hauptthemen laut MEDLINE: Multiple Myeloma, ADP-ribosyl Cyclase 1, Molecular Imaging, Molecular Probes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 88 Literaturangaben. Gefördert von: Soochow University, High Level Innovation and Entrepreneurial Research Team Program in Jiangsu, Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Multiple myeloma (MM), the second most common hematologic malignancy, often presents with a gradual onset and minimal symptoms in its early stages, leading to frequent misdiagnosis and delays in treatment. In recent years, radionuclide-based molecular imaging has emerged as a pivotal tool in the noninvasive evaluation and clinical management of MM, particularly in assessing the expression of CD38─a transmembrane glycoprotein that is robustly expressed on approximately 80-100% of malignant plasma cells. Notably, clinical studies have revealed a negative correlation between CD38 expression levels and treatment outcomes, underscoring the importance of accurate and dynamic measurement of CD38 for diagnostic precision and individualized treatment stratification. Radiolabeled molecular imaging targeting CD38 enables repeated, in vivo assessments of its expression status, allowing clinicians to monitor molecular heterogeneity and temporal changes throughout disease progression or therapeutic intervention. To this end, a variety of CD38-targeted imaging agents have been developed, including monoclonal antibodies, antibody fragments, nanobodies and peptide. Many of these probes are currently undergoing preclinical evaluation or have entered early phase clinical trials. This review summarizes recent advances in the development and application of CD38-targeted molecular imaging probes in MM, highlighting their potential to improve disease characterization, therapeutic monitoring, and personalized management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, NO.899 Pinghai Road, Suzhou 215006, China.
- National Institution of Drug Clinical Trial, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
- State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China.
- Institute for Interdisciplinary Drug Research and Translational Sciences, Soochow University, Suzhou 215006, China.
- Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, NO.899 Pinghai Road, Suzhou 215006, China.
ORCID-Profile: Shushan Ge, Shihong Li, Liyan Miao
Förderung
- Soochow University
- High Level Innovation and Entrepreneurial Research Team Program in Jiangsu
- Ministry of Science and Technology of the People's Republic of China
- the Jiangsu Provincial Science and Technology Plan Special Fund
- Science and Technology Plan of Suzhou
- the Jiangsu Provincial Medical Key Discipline
- the Project of State Key Laboratory of Radiation Medicine and Protection, Soochow University
Zitieren
APA
Zheng, M., Zhang, K., Mu, H., Liu, Q., Ge, S., Shan, Y., Ma, H., Peng, X., Li, S., Zhang, H., Wang, Y., & Miao, L. (2026). CD38-Targeted Molecular Imaging Probes for Multiple Myeloma: Advances, Challenges, and Opportunities. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01232
Vancouver
Zheng M, Zhang K, Mu H, Liu Q, Ge S, Shan Y, et al. CD38-Targeted Molecular Imaging Probes for Multiple Myeloma: Advances, Challenges, and Opportunities. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01232
BibTeX
@article{Zheng2026,
author = {Zheng, Meng and Zhang, Kaijie and Mu, Huiwen and Liu, Qingfeng and Ge, Shushan and Shan, Yuanyuan and Ma, Haoqun and Peng, Xuanhui and Li, Shihong and Zhang, Hua and Wang, Yan and Miao, Liyan},
title = {CD38-Targeted Molecular Imaging Probes for Multiple Myeloma: Advances, Challenges, and Opportunities},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01232}
}
EUVIMED